# Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

> **NCT04135092** · — · NO_LONGER_AVAILABLE · sponsor: **National Institutes of Health Clinical Center (CC)**

## Conditions studied

_None listed._

## Interventions

- **BIOLOGICAL:** Individual Patient TCR Transduced PBL
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Aldesleukin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04135092
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04135092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04135092, "Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04135092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*